This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dussán, K. Articles by Petri, M Search for Related Content PubMed PubMed Citation Articles by Dussán, K. Articles by Petri, M Social Bookmarking                         What's this?

High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures

Michigan State College of Human Medicine, East Lansing, Michigan

L Magder

Associate Professor and Head of the Division Biostatistics and Bioinformatics, University of Maryland School of Medicine, Baltimore, Maryland

RA Brodsky

Associate Professor of Medicine and Oncology, Director, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland

RJ Jones

Professor, Medicine and Oncology, Director, BMT Program, Johns Hopkins University School of Medicine, Maryland

M Petri

Professor Division of Rheumatology, Department of Medicine, Co-Director Hopkins Lupus Pregnancy Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

In spite of current therapies, the overall health status of patients with SLE is poor. High-dose cyclophosphamide (50 mg/kg for 4 days) with or without stem-cell rescue has been introduced as a new therapy for severe SLE, including renal and central nervous system (CNS)-SLE. Long-term durable responses have been found to be 40%. A randomised clinical trial was completed comparing high-dose cyclophosphamide with monthly intravenous cyclophosphamide (750 mg/m squared bovine serum albumin) in patients with SLE who need cyclophosphamide for the first time. The primary outcome of the trial was complete clinical response. In this report, we compare the treatment groups with respect to quality of life. The patients in this study had a mean age of 35.3 ± 10.1 years, were of Caucasian (35%), African-American (51%), Hispanic (8%) and Asian (6%) people, and 88% were women. The organ leading to treatment was renal lupus in 29%, CNS-lupus in 45% and other organs in 26%. Quality of life was measured at each visit using the Medical Outcome Study Short-Form 36 (SF-36). At 6 months, the patients in the high-dose cyclophosphamide trial arm had significantly greater improvement than patients in the monthly intravenous cyclophosphamide arm (P = 0.026; P = 0.0082, respectively) in the categories of general health and social functioning. At 18 months, the improvement in the role-physical score was significantly greater in the high-dose cyclophosphamide trial arm than in the monthly-dose cyclophosphamide arm (P = 0.025). At the end of the two and a half-year study, there were no significant differences between the groups with respect to changes in SF-36. By pooling the groups, at 30 months, there was a statistically significant (P < 0.05) improvement over baseline in 6 of the 8 SF-36 domains. This study shows earlier improvement in SF-36 measures at 6 months in the high-dose cyclophosphamide group but equal improvement in both arms at two and one and a half years. Eventual improvements in quality-of-life with both cyclophosphamide regimens are clinically meaningful to both patients and treating physicians.

Key Words: quality of life • renal lupus • systemic lupus erythematosus

Lupus, Vol. 17, No. 12, 1079-1085 (2008)
DOI: 10.1177/0961203308093828


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?